BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma

  Aura Biosciences announced new interim safety and efficacy data from an open-label Phase 1b/2 study of its lead program, light-activated AU-011 for the treatment of primary choroidal melanoma.

  June 17, 2018

   · 

  5 min read
• Policy

  A diabetes diagnosis later in life may signal early pancreatic cancer in African Americans and Latinos

  A new study from the Keck School of Medicine of USC shows that African Americans and Latinos who are diagnosed with diabetes after age 50 are at increased risk of developing one of the deadliest forms of cancer

  June 17, 2018

   · 

  2 min read
• FDA

  Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar

  Celltrion has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab).

  June 17, 2018

   · 

  3 min read
• Policy

  Rep. Reed Breaks with GOP to Defend Pre-Existing Conditions

  Congressman Tom Reed (R-NY) joined Matter of Fact with Soledad O’Brien on Sunday to voice his opposition of the Justice Department’s decision to not defend the Obamacare individual mandate.

  June 17, 2018

   · 

  2 min read
• Drug Development

  Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm

  Aprea Therapeutics presented results at the 2018 EHA Annual Meeting from its Phase Ib/II clinical study in MDS.

  June 17, 2018

   · 

  5 min read
• Drug Development

  Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma

  Bristol-Myers Squibb Company announced that the ELOQUENT-3 trial, an international Phase 2 study evaluating the addition of Empliciti (elotuzumab) to pomalidomide and low-dose dexamethasone (EPd) in patients with relapsed/refractory multiple myeloma (RRMM), achieved its primary endpoint,

  June 17, 2018

   · 

  12 min read